Shekelle Paul G, Morton Sally C, Jungvig Lara K, Udani Jay, Spar Myles, Tu Wenli, J Suttorp Marika, Coulter Ian, Newberry Sydne J, Hardy Mary
Southern California Evidence-Based Practice Center, Rand Corporation, Santa Monica, California, USA.
J Gen Intern Med. 2004 Apr;19(4):380-9. doi: 10.1111/j.1525-1497.2004.30090.x.
To evaluate and synthesize the evidence on the effect of supplements of vitamin E on the prevention and treatment of cardiovascular disease.
Systematic review of placebo-controlled randomized controlled trials; meta-analysis where justified.
Eighty-four eligible trials were identified. For the outcomes of all-cause mortality, cardiovascular mortality, fatal or nonfatal myocardial infarction, and blood lipids, neither supplements of vitamin E alone nor vitamin E given with other agents yielded a statistically significant beneficial or adverse pooled relative risk (for example, pooled relative risk of vitamin E alone = 0.96 [95% confidence interval (CI), 0.84 to 1.10]; 0.97 [95% CI, 0.80 to 1.90]; and 0.72 [95% CI, 0.51 to 1.02] for all-cause mortality, cardiovascular mortality, and nonfatal myocardial infarction, respectively.
There is good evidence that vitamin E supplementation does not beneficially or adversely affect cardiovascular outcomes.
评估并综合有关维生素E补充剂对心血管疾病预防和治疗效果的证据。
对安慰剂对照的随机对照试验进行系统评价；在合理的情况下进行荟萃分析。
共确定了84项符合条件的试验。对于全因死亡率、心血管疾病死亡率、致命或非致命性心肌梗死以及血脂等结果，单独使用维生素E补充剂或与其他药物联合使用维生素E均未产生具有统计学意义的有益或有害合并相对风险（例如，单独使用维生素E时，全因死亡率、心血管疾病死亡率和非致命性心肌梗死的合并相对风险分别为0.96[95%置信区间(CI)，0.84至1.10]；0.97[95%CI，0.80至1.90]；以及0.72[95%CI，0.51至1.02]）。
有充分证据表明，补充维生素E对心血管疾病结局无有益或有害影响。
